Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human Kallikrein 1 Antibodies:
anti-Mouse (Murine) Kallikrein 1 Antibodies:
anti-Rat (Rattus) Kallikrein 1 Antibodies:
Go to our pre-filtered search.
Human Polyclonal Kallikrein 1 Primary Antibody for ELISA, WB - ABIN252921
Gao, Clermont, Rook, Fonda, Srinivasan, Wojtkowski, Fujimoto, Avery, Arrigg, Bursell, Aiello, Feener: Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. in Nature medicine 2007
Show all 2 Pubmed References
Mouse (Murine) Polyclonal Kallikrein 1 Primary Antibody for ELISA, IP - ABIN4227986
Christophi, Isackson, Blaber, Blaber, Rodriguez, Scarisbrick: Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. in Journal of neurochemistry 2004
Our results indicate that during severe sepsis and septic shock, a decrease in plasma concentrations of kallistatin (show SERPINA4 Antibodies) reflects increased severity and poorer outcome of disease.
data suggest that overexpression of kallistatin (show SERPINA4 Antibodies) interferes with lymphopoiesis, ultimately impacting the level of circulating CD19 (show CD19 Antibodies)(+) B lymphocytes.
Recognition of anti-tumor necrosis factor-alpha (TNF-alpha) or Kallikrein Inhibitor may lead to therapeutics to enhance existing treatments for patients who do not respond to anti-vascular endothelial growth factor (VEGF) therapies.
increasing the serum levels of AngII increased the risk of acute myocardial infarction (AMI (show CFD Antibodies)); the risk of AMI (show CFD Antibodies) increased when the serum levels of AngII and KLK1 simultaneously increased; individuals with the combined genotypes of ACE (show ACE Antibodies) DD and KLK1 GG showed increased risk of AMI (show CFD Antibodies) compared with those with the combined genotypes of ACE (show ACE Antibodies) II and KLK1 AA
The rs5516 G allele of KLK1 was significantly associated with aortic aneurysm
Kallistatin (show SERPINA4 Antibodies) levels were correlated with some markers of systemic inflammation in the HIV population.
KLK1 rs5516 SNP is not related to the incidence of Alzheimer's disease in a Hunan Han Chinese population.
TK promoted cell survival and beta-catenin (show CTNNB1 Antibodies) degradation in serum-starved SH-SY5Y cells via increasing autophagy.
Increased kallistatin (show SERPINA4 Antibodies) levels in type 1 diabetes and its relation with carotid intima media thickness may reflect vascular dysfunction and suggest a link between micro- and macro-angiopathy.
reveal novel mechanisms of kallistatin (show SERPINA4 Antibodies) in inducing apoptosis and autophagy in breast cancer cells
Polypeptides identified based on immunorecognition by autoantibodies in sera from IQI/Jic mice affected with autoimmune disease (>12 weeks of age) were tissue kallikrein (Klk)-1 and -13 and were cross-reactive to the autoantibodies.
Protective effects of Tissue kallikrein gene transfer on ischemic diseases.
TK, like several other proteases, can activate ENaC (show SCNN1A Antibodies) in the kidney and the colon.
Tissue kallikrein and kinins do not influence the trophicity of kidneys, the synthesis and secretion of renin (show REN Antibodies), blood pressure increase, and cardiac remodeling due to renin (show REN Antibodies) angiotensin system activation.
tissue kallikrein knockout mice had a significant two-fold increase in albuminuria
The study suggests that kallikrein plays an antihypertensive role in hyperaldosteronism.
These data do not support a role for the TK-kinin system, protective or deleterious, in the development of insulin (show INS Antibodies) resistance and diabetes.
Lower excretion of active renin (show REN Antibodies) and prorenin in TK(-/-) compared to TK(+/+) suggest coordinated regulation of the two proteins in their participation to collecting duct function.
Plasma kallikrein (show KLKB1 Antibodies)-deficient mice challenged with transient middle cerebral artery occlusion developed significantly smaller brain infarctions.
The data of this study presented support the conclusion that Klk6 is an important participant in the immunopathogenic events that drive TMEV-IDD (show DGS2 Antibodies) at acute through early chronic time points.
Inhibits human amidolytic and kininogenase activities of tissue kallikrein. Inhibition is achieved by formation of an equimolar, heat- and SDS-stable complex between the inhibitor and the enzyme, and generation of a small C-terminal fragment of the inhibitor due to cleavage at the reactive site by tissue kallikrein.
, glandular kallikrein 1
, kallikrein 1, renal/pancreas/salivary
, kallikrein serine protease 1
, kidney/pancreas/salivary gland kallikrein
, tissue kallikrein
, glandular kallikrein K1
, kallikrein 6
, kallikrein renal/pancreas/salivary
, renal kallikrein
, tissue kallikrein-6
, true tissue kallikrein
, glandular kallikrein
, PS kallikrein
, kallikrein 1-related peptidase b3
, nerve growth factor gamma chain
, nerve growth factor gamma polypeptide
, pancreatic kallikrein
, kallikrein inhibitor
, peptidase inhibitor 4
, protease inhibitor 4 (kallistatin)
, serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4
, serpin A4